196 related articles for article (PubMed ID: 8490080)
1. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Brunner G; Arnold R; Hennig U; Fuchs W
Aliment Pharmacol Ther; 1993; 7 Suppl 1():51-5, discussion 61-6. PubMed ID: 8490080
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
Brunner GH; Lamberts R; Creutzfeldt W
Digestion; 1990; 47 Suppl 1():64-8; discussion 76. PubMed ID: 2093018
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Brunner G; Harke U
Aliment Pharmacol Ther; 1994; 8 Suppl 1():59-64. PubMed ID: 8180296
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
Brunner G; Creutzfeldt W
Scand J Gastroenterol Suppl; 1989; 166():101-5; discussion 111-3. PubMed ID: 2513641
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
[TBL] [Abstract][Full Text] [Related]
6. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
Brunner G; Creutzfeldt W; Harke U; Lamberts R
Digestion; 1988; 39(2):80-90. PubMed ID: 3410170
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of Lansoprazole: the US clinical trial experience.
Freston JW; Rose PA; Heller CA; Haber M; Jennings D
Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
12. Effect of lansoprazole on peptic ulcers.
Ohashi T; Sakata J; Haraguchi Y; Eto T
J Clin Gastroenterol; 1995; 20 Suppl 2():S83-5. PubMed ID: 7594350
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
14. Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial.
Michel P; Lemaire M; Colin R; Bommelaer G; Rambaud JC; Dupas JL; Bigard MA; Verwaerd JC
Aliment Pharmacol Ther; 1994 Feb; 8(1):119-22. PubMed ID: 8186337
[TBL] [Abstract][Full Text] [Related]
15. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Agrawal NM; Campbell DR; Safdi MA; Lukasik NL; Huang B; Haber MM
Arch Intern Med; 2000 May; 160(10):1455-61. PubMed ID: 10826458
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
17. Rapid healing of gastric ulcers with lansoprazole.
Bardhan KD; Ahlberg J; Hislop WS; Lindholmer C; Long RG; Morgan AG; Sjostedt S; Smith PM; Stig R; Wormsley KG
Aliment Pharmacol Ther; 1994 Apr; 8(2):215-20. PubMed ID: 8038354
[TBL] [Abstract][Full Text] [Related]
18. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Meining A; Kiel G; Stolte M
Aliment Pharmacol Ther; 1998 Aug; 12(8):735-40. PubMed ID: 9726386
[TBL] [Abstract][Full Text] [Related]
19. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Russo A; Dattilo M
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
[TBL] [Abstract][Full Text] [Related]
20. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Londong W; Barth H; Dammann HG; Hengels KJ; Kleinert R; Müller P; Rohde H; Simon B
Aliment Pharmacol Ther; 1991 Jun; 5(3):245-54. PubMed ID: 1888824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
